Erroneous activation of cGAS has been implicated in a multitude of autoimmune diseases, including systemic lupus erythematous and Aicardi-Goutières Syndrome, positioning cGAS inhibition as a potentially significant therapeutic strategy (Chu et al., 2021). This evidence concerns the gene CGAS and Aicardi-Goutieres syndrome.